Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Camurus AB
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Male or female patient, ≥18 years at screening
Diagnosis of PLD (associated with ADPKD or isolated as in ADPLD) as defined by htTLV ≥1800 mL/m at screening
Presence of at least 1 of the following PLD-related symptoms within 2 weeks before screening: bloating, fullness in abdomen, lack of appetite, feeling full quickly after beginning to eat, acid reflux, nausea, rib cage pain or pressure, pain in side, abdominal pain, back pain, shortness of breath after physical exertion, limited in mobility, concern about abdomen getting larger, dissatisfied by the size of abdomen
Not a candidate for, or not willing to undergo, surgical intervention for hepatic cysts during the trial
You may not be if
Surgical intervention for PLD within 3 months before screening
Treatment with a somatostatin analogue (SSA) within 3 months before screening
Non-responsive to previous treatment of PLD with an SSA as per the Investigator's assessment
Systematic cholelithiasis within 3 months before screening or previous medical history of cholelithiasis induced by SSAs unless treated with cholecystectomy
Presence of extrahepatic cysts that, in the Investigator's opinion, may prevent the patient from safely participating in the trial
Severe kidney disease, as defined by eGFR \<30 mL/min/1.73\^m2
Severe liver disease defined as liver cirrhosis of Child-Pugh class C
Any other current or prior medical condition that may interfere with the conduct of the trial or the evaluation of its results in the opinion of the Investigator
Clareo Health | A Trial to Assess the Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With PLD
